Maze Therapeutics, Inc.
MAZE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1 | $0 | $0 |
| Gross Profit | $0 | -$1 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $25 | $28 | $28 | $22 |
| G&A Expenses | $8 | $8 | $8 | $8 |
| SG&A Expenses | $8 | $8 | $8 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1 | $0 | $0 |
| Operating Expenses | $33 | $36 | $35 | $30 |
| Operating Income | -$33 | -$36 | -$35 | -$30 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3 | $3 | $3 | -$0 |
| Pre-Tax Income | -$30 | -$34 | -$33 | -$30 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$30 | -$34 | -$33 | -$30 |
| % Margin | – | – | – | – |
| EPS | -0.66 | -0.77 | -0.749 | -0.112 |
| % Growth | 14.3% | -2.9% | -568.4% | – |
| EPS Diluted | -0.66 | -0.77 | -0.749 | -0.112 |
| Weighted Avg Shares Out | 46 | 44 | 44 | 44 |
| Weighted Avg Shares Out Dil | 46 | 44 | 44 | 44 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $3 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$30 | -$33 | -$35 | -$29 |
| % Margin | – | – | – | – |